PMID- 28820389 OWN - NLM STAT- MEDLINE DCOM- 20180509 LR - 20211204 IS - 1899-1505 (Electronic) IS - 0867-5910 (Linking) VI - 68 IP - 3 DP - 2017 Jun TI - Hippo pathway - brief overview of its relevance in cancer. PG - 311-335 AB - The Hippo pathway is the major regulator of organ growth and proliferation. Described initially in Drosophila, it is now recognized as one of the most conserved molecular pathways in all metazoan. Recent studies have revealed the Hippo signalling pathway might contribute to tumorigenesis and cancer development. The core components of the Hippo pathway include the mammalian sterile 20-like kinases (MSTs), large tumour suppressor kinases (LATSs), the adaptor proteins Salvador homologue 1 (SAV1, also called WW45) and Mps One Binder kinase activator proteins. The major target of the Hippo core kinases is the mammalian transcriptional activator Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ). In cancer, the Hippo signalling is inactivated and YAP and TAZ are activated and free to translocate into the nucleus to promote cell proliferation. Nuclear YAP/TAZ activate or suppress transcription factors that regulate target genes involved in cell proliferation, tissue growth, control of organ size and shape or metastasis. The Hippo signalling pathway that controls the most important cellular processes like growth and division appears to be a very promising research subject in the field of cell biology and tissue engineering. It consists of elements that in the cell play the roles of tumour suppressors as well as oncogenes. This 'Janus like' - an opposite activity hidden within one and the same signalling pathway represents a significant obstacle for studying it. This property of the Hippo pathway is worth remembering, as it will appear several times during the discussion of its properties. Here, we will review certain data regarding biology of the Hippo signalling and its interplay with other prominent signalling pathways in the cell, its relevance in cancer development and therapies that might target elements of the Hippo pathway in most human cancers. FAU - Zygulska, A L AU - Zygulska AL AD - Department of Oncology, University Hospital, Jagiellonian University Medical College, Cracow, Poland. FAU - Krzemieniecki, K AU - Krzemieniecki K AD - Department of Oncology Jagiellonian University Medical College, Cracow, Poland. FAU - Pierzchalski, P AU - Pierzchalski P AD - Faculty of Health Science, Department of Medical Physiology, Jagiellonian University Medical College, Cracow, Poland. piotr.pierzchalski@uj.edu.pl. LA - eng PT - Journal Article PT - Review PL - Poland TA - J Physiol Pharmacol JT - Journal of physiology and pharmacology : an official journal of the Polish Physiological Society JID - 9114501 RN - 0 (Intracellular Signaling Peptides and Proteins) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) SB - IM MH - Animals MH - Carcinogenesis MH - Cell Polarity MH - Humans MH - Intracellular Signaling Peptides and Proteins/*metabolism MH - Neoplasms/*metabolism MH - Organ Size MH - Protein Serine-Threonine Kinases/*metabolism MH - Signal Transduction EDAT- 2017/08/19 06:00 MHDA- 2018/05/10 06:00 CRDT- 2017/08/19 06:00 PHST- 2016/06/28 00:00 [received] PHST- 2017/04/29 00:00 [accepted] PHST- 2017/08/19 06:00 [entrez] PHST- 2017/08/19 06:00 [pubmed] PHST- 2018/05/10 06:00 [medline] PST - ppublish SO - J Physiol Pharmacol. 2017 Jun;68(3):311-335.